1. A 38-year-old man with schizophrenia, well controlled on haloperidol 5 mg twice daily, is prescribed terbinafine 250 mg once daily for toenail onychomycosis. His psychiatrist is concerned about a potential drug interaction. Haloperidol is metabolized substantially by CYP2D6 and prolongs the QTc interval in a concentration-dependent manner. Which of the following best describes the expected pharmacokinetic consequence and the primary clinical risk of this combination?
A) Terbinafine induces CYP2D6, accelerating haloperidol metabolism and reducing its plasma concentrations; the primary clinical risk is worsening psychosis from subtherapeutic haloperidol levels
B) Terbinafine competitively inhibits CYP3A4, which is the dominant elimination pathway for haloperidol; the resulting accumulation produces sedation but does not affect the QTc interval because QTc prolongation by haloperidol is independent of plasma concentration
C) Terbinafine has no clinically meaningful effect on haloperidol pharmacokinetics because haloperidol is predominantly eliminated by renal excretion and is not significantly metabolized by CYP2D6 at therapeutic doses
D) Terbinafine's potent mechanism-based inhibition of CYP2D6 reduces haloperidol clearance, causing plasma haloperidol concentrations to rise; elevated haloperidol concentrations increase the risk of QTc prolongation and potentially fatal ventricular arrhythmia
E) Terbinafine inhibits both CYP2D6 and CYP2C9, producing additive inhibition of haloperidol metabolism; however, because haloperidol has a wide therapeutic index for cardiac effects, dose adjustment is not required unless the QTc exceeds 500 milliseconds
ANSWER: D
Rationale:
Terbinafine is a potent mechanism-based (irreversible) inhibitor of CYP2D6. Haloperidol undergoes significant CYP2D6-mediated metabolism as one of its primary clearance pathways; when CYP2D6 activity is substantially reduced by terbinafine, haloperidol clearance falls and plasma concentrations rise. Haloperidol prolongs the cardiac QTc interval in a concentration-dependent manner — higher plasma haloperidol concentrations produce greater QTc prolongation, increasing the risk of torsades de pointes and potentially fatal ventricular arrhythmia. This interaction requires either monitoring of haloperidol plasma levels and ECG during terbinafine co-administration, a haloperidol dose reduction, or consideration of an alternative antifungal agent. The inhibitory effect of terbinafine on CYP2D6 persists for weeks after discontinuation, requiring continued monitoring after terbinafine is stopped.
Option A: Option A is incorrect because terbinafine inhibits rather than induces CYP2D6; CYP2D6 induction would reduce haloperidol levels and could worsen psychosis, but the actual pharmacological effect is the opposite — inhibition increases haloperidol exposure.
Option B: Option B is incorrect because terbinafine's primary CYP interaction is CYP2D6 inhibition, not CYP3A4 inhibition, and haloperidol QTc prolongation is concentration-dependent — higher concentrations produce greater QTc prolongation, making accumulation directly relevant to cardiac safety.
Option C: Option C is incorrect because haloperidol is substantially metabolized by CYP2D6 at therapeutic doses; it is not primarily renally excreted, and terbinafine's CYP2D6 inhibition has well-documented effects on haloperidol pharmacokinetics.
Option E: Option E is incorrect because terbinafine does not clinically inhibit CYP2C9 to a meaningful degree; its relevant interaction is CYP2D6, and haloperidol does not have a wide therapeutic index for QTc effects — concentration-dependent QTc prolongation with haloperidol is a recognized safety concern requiring proactive management.
2. A patient with cryptococcal meningitis is receiving amphotericin B deoxycholate plus flucytosine induction therapy. On day 5, serum creatinine rises from 0.9 to 2.4 mg/dL, consistent with amphotericin B-related nephrotoxicity. The team asks how flucytosine dosing should be managed. Which approach is most appropriate?
A) Discontinue flucytosine immediately and complete the remaining induction with amphotericin B monotherapy, because any degree of renal impairment renders flucytosine too dangerous to continue
B) Use TDM (therapeutic drug monitoring) of flucytosine — measuring 2-hour post-dose peak concentrations and adjusting the dose or interval to maintain levels within 25 to 50 mg/L — rather than relying on fixed creatinine-based dose tables, because rapidly changing renal function makes estimated clearance calculations unreliable
C) Continue flucytosine at the full dose of 25 mg/kg every 6 hours without modification, because the nephrotoxicity is caused by amphotericin B rather than flucytosine and renal impairment from one drug does not affect clearance of a different drug
D) Switch to intravenous flucytosine and reduce the total daily dose by 25%; intravenous administration bypasses the renal clearance pathway by delivering drug directly to the systemic circulation and minimizes further accumulation
E) Reduce the flucytosine dose empirically to 12.5 mg/kg every 6 hours for all patients with serum creatinine above 2.0 mg/dL and recheck creatinine in 72 hours before further adjustment, without obtaining flucytosine drug levels
ANSWER: B
Rationale:
Flucytosine is eliminated almost entirely by renal excretion of unchanged drug; more than 90% of a dose appears in urine as intact flucytosine. When amphotericin B causes nephrotoxicity and creatinine rises, flucytosine clearance falls proportionally, causing plasma flucytosine concentrations to increase. In this setting, standard creatinine-based dose-adjustment tables are unreliable because they assume stable renal function and estimate clearance from a static creatinine value; when renal function is changing rapidly — as in amphotericin B-induced nephrotoxicity — the creatinine measured today may not reflect the clearance available in 12 hours. TDM with direct measurement of 2-hour post-dose peak concentrations is the most reliable approach to maintaining flucytosine within the therapeutic window of 25 to 50 mg/L peak while keeping troughs below 100 mg/L to prevent concentration-dependent myelosuppression.
Option A: Option A is incorrect because flucytosine should not be reflexively discontinued at any rise in creatinine; TDM-guided dose adjustment allows its continuation with appropriate monitoring, and removing it from the regimen eliminates the proven survival benefit of combination induction therapy.
Option C: Option C is incorrect because even though the nephrotoxicity is caused by amphotericin B, the resulting reduction in GFR (glomerular filtration rate) directly impairs flucytosine renal clearance — a drug's source of toxicity does not determine which co-administered renally cleared drugs are affected by the resulting renal impairment.
Option D: Option D is incorrect because the route of flucytosine administration (oral vs. intravenous) does not affect renal clearance; flucytosine is cleared renally regardless of how it is administered, and switching routes does not address the pharmacokinetic problem of accumulation due to reduced renal elimination.
Option E: Option E is incorrect because empiric dose reduction without drug level measurement does not confirm whether the adjusted dose achieves or maintains therapeutic concentrations; in a patient with actively changing renal function, TDM provides the only reliable real-time assessment of actual drug exposure.
3. A 29-year-old woman presents to the emergency department with severe abdominal pain, confusion, and dark urine two weeks after starting griseofulvin for tinea capitis. Her past medical history is notable only for a single prior episode of unexplained abdominal pain five years ago that resolved spontaneously. Urine porphyrins are markedly elevated. Which mechanism explains why griseofulvin is contraindicated in patients with porphyria, and what does this case illustrate about latent porphyria?
A) Griseofulvin induces hepatic delta-aminolevulinic acid synthase (ALA-S1), the rate-limiting enzyme of the heme biosynthesis pathway; in patients with a partial enzymatic defect in a downstream step (latent porphyria), this induction overwhelms the pathway's capacity, causing toxic porphyrin precursor accumulation and precipitating an acute porphyric crisis even in a patient with no prior formal diagnosis
B) Griseofulvin directly inhibits uroporphyrinogen decarboxylase (UROD), the enzyme deficient in porphyria cutanea tarda; the drug's structural similarity to uroporphyrinogen allows it to competitively block the enzyme and acutely reduces heme production, triggering feedback induction of the entire porphyrin synthesis pathway
C) Griseofulvin is metabolized by CYP3A4 to a reactive epoxide intermediate that covalently binds to and inactivates ferrochelatase, the terminal enzyme of heme biosynthesis; protoporphyrin IX accumulates as a result, producing the clinical and biochemical features of an acute attack
D) Griseofulvin chelates free iron in the liver, depleting the substrate required for ferrochelatase-mediated heme synthesis; the resulting iron deficiency triggers compensatory upregulation of the entire porphyrin synthesis pathway, producing precursor accumulation in a patient with underlying partial enzyme deficiency
E) Griseofulvin activates the pregnane X receptor (PXR) in hepatocytes, which directly transcriptionally upregulates all porphyrin synthesis genes simultaneously; the resulting coordinate induction of the entire pathway produces constitutional symptoms of porphyria in any patient regardless of underlying enzymatic status
ANSWER: A
Rationale:
Griseofulvin induces hepatic delta-aminolevulinic acid synthase (ALA-S1), the rate-limiting and first committed enzyme of the heme biosynthesis pathway. In individuals with normal heme synthesis, this induction is well tolerated because all downstream enzymatic steps have sufficient capacity to process the increased flux of porphyrin precursors through to heme. However, in patients with latent porphyria — who carry a partial loss-of-function mutation in one of the downstream biosynthetic enzymes — the increased flux produced by ALA-S1 induction exceeds the reduced capacity of the defective step. Porphyrin precursors (particularly ALA and porphobilinogen in acute porphyrias) accumulate to toxic concentrations, precipitating an acute attack with the triad of abdominal pain, neuropsychiatric symptoms, and dark urine. This case illustrates that latent porphyria can remain completely asymptomatic until a precipitating drug challenge reveals the underlying enzymatic vulnerability. The prior unexplained abdominal pain episode five years ago is consistent with a previous sub-threshold or spontaneously resolving acute porphyric episode, suggesting latent disease that was not formally investigated. Griseofulvin is therefore absolutely contraindicated in all patients with known or suspected porphyria.
Option B: Option B is incorrect because griseofulvin does not directly inhibit uroporphyrinogen decarboxylase (UROD); competitive inhibition of UROD by griseofulvin is not the established mechanism, and UROD inhibition is the mechanism of porphyria cutanea tarda, which has a distinct clinical presentation from the acute attack described here.
Option C: Option C is incorrect because while griseofulvin undergoes CYP3A4-mediated metabolism, its porphyrinogenic mechanism is ALA-S1 induction rather than reactive epoxide formation inactivating ferrochelatase; ferrochelatase inhibition causes protoporphyria, not the acute attack syndrome described in this patient.
Option D: Option D is incorrect because iron chelation is not the established porphyrinogenic mechanism of griseofulvin; iron depletion can worsen porphyria cutanea tarda in some contexts, but the mechanism here is ALA-S1 induction, not substrate depletion.
Option E: Option E is incorrect because while griseofulvin does activate CYP-inducing pathways, the porphyrinogenic effect is not a coordinate transcriptional upregulation of all porphyrin genes producing attacks in all patients — it is specifically ALA-S1 induction that produces attacks selectively in patients with underlying partial enzyme deficiency in downstream steps.
4. A resident compares the mechanisms of flucytosine and methotrexate, noting that both ultimately impair thymidylate synthesis. An attending asks the resident to identify the key difference that explains why flucytosine disrupts both DNA and RNA synthesis while methotrexate primarily disrupts DNA synthesis. Which statement correctly distinguishes the two mechanisms?
A) Methotrexate is incorporated into RNA as a false nucleotide in the same manner as flucytosine's FUTP metabolite, but methotrexate's RNA incorporation is pharmacologically negligible because methotrexate is rapidly deaminated back to uracil by RNA nucleotidases; flucytosine's FUTP is resistant to this deamination and therefore produces sustained RNA disruption
B) Flucytosine and methotrexate both inhibit thymidylate synthase directly as the mechanism responsible for their respective DNA synthesis effects; the difference is that methotrexate is additionally incorporated into DNA as a false base, disrupting DNA structure, whereas flucytosine has no direct DNA incorporation
C) Both drugs inhibit dihydrofolate reductase (DHFR) as their primary mechanism; flucytosine also inhibits DHFR in mitochondria while methotrexate is confined to cytoplasmic DHFR, and the mitochondrial DHFR inhibition by flucytosine is responsible for additional RNA disruption through impaired mitochondrial transcription
D) Methotrexate inhibits thymidylate synthase directly at the enzyme active site with the same covalent mechanism as FdUMP; flucytosine additionally disrupts RNA through FUTP incorporation, but this RNA effect is clinically irrelevant because ribosomal RNA turnover is too slow for FUTP to accumulate to significant levels during a standard treatment course
E) Methotrexate inhibits dihydrofolate reductase (DHFR), depleting the reduced folate pool required for thymidylate synthase to function and thereby blocking DNA synthesis — but does not produce a false nucleotide that incorporates into RNA; flucytosine generates both FdUMP (which inhibits thymidylate synthase) and FUTP (fluorouridine triphosphate), which is directly incorporated into nascent RNA, disrupting RNA structure and protein synthesis through a mechanism entirely distinct from DHFR inhibition
ANSWER: E
Rationale:
The distinction between methotrexate and flucytosine at the level of nucleic acid synthesis is mechanistically important. Methotrexate inhibits dihydrofolate reductase (DHFR), which depletes the reduced folate cofactor (5,10-methylenetetrahydrofolate) required for thymidylate synthase to methylate dUMP to dTMP (thymidine monophosphate). Without thymidine, DNA synthesis halts — this is methotrexate's primary mechanism. Methotrexate does not generate a fluorinated nucleotide and does not incorporate into RNA as a false base. Flucytosine, by contrast, is converted intracellularly to 5-fluorouracil (5-FU), which diverges into two active metabolite pathways. In the first, 5-FU is converted to FdUMP (fluorodeoxyuridine monophosphate), which directly and covalently inhibits thymidylate synthase — a mechanism that converges on the same enzymatic step as methotrexate but reaches it through a different route. In the second, 5-FU is converted to FUTP (fluorouridine triphosphate), which is directly incorporated into RNA in place of UTP, disrupting ribosomal and messenger RNA structure and impairing protein synthesis. This second pathway — RNA disruption through false nucleotide incorporation — has no equivalent in the methotrexate mechanism and accounts for the dual-target activity of flucytosine.
Option A: Option A is incorrect because methotrexate is not incorporated into RNA as a false nucleotide; methotrexate is a folate analogue that acts through DHFR inhibition, not through nucleotide incorporation into either DNA or RNA.
Option B: Option B is incorrect because methotrexate does not directly inhibit thymidylate synthase at its active site; it acts upstream by depleting the folate cofactor required for thymidylate synthase activity, and methotrexate is not incorporated into DNA as a false base.
Option C: Option C is incorrect because flucytosine does not inhibit DHFR at all; its mechanism bypasses DHFR entirely, with FdUMP acting directly on thymidylate synthase, and neither drug exerts its primary effect through mitochondrial DHFR inhibition.
Option D: Option D is incorrect because methotrexate does not inhibit thymidylate synthase through the same covalent FdUMP mechanism — it acts through DHFR to deplete the cofactor rather than forming a covalent ternary complex with the enzyme — and FUTP incorporation into RNA is a clinically significant mechanism contributing to flucytosine's antifungal activity, not a negligible effect.
5. A 45-year-old woman completed a 12-week course of terbinafine three weeks ago. Her primary care physician now initiates paroxetine (a selective serotonin reuptake inhibitor (SSRI) and also a CYP2D6 substrate) for a new diagnosis of major depressive disorder. The physician asks whether the prior terbinafine course has any remaining pharmacokinetic relevance. Which of the following best explains the clinical concern?
A) There is no remaining pharmacokinetic concern because terbinafine's half-life is approximately 17 hours and after three weeks (approximately 28 half-lives) all terbinafine has been eliminated from the body, restoring CYP2D6 to baseline activity
B) Terbinafine accumulates permanently in nail keratin and continues to release slowly into the systemic circulation for months after the last dose; systemic terbinafine concentrations at three weeks post-treatment remain sufficient to maintain significant CYP2D6 inhibition
C) Because terbinafine produces mechanism-based irreversible inactivation of CYP2D6, recovery of enzyme activity depends on de novo synthesis of new CYP2D6 protein rather than on drug elimination; three weeks after stopping terbinafine, significant CYP2D6 inhibition may persist, and paroxetine — itself a CYP2D6 substrate — may accumulate to higher-than-expected concentrations
D) Terbinafine's residual CYP2D6 inhibition at three weeks applies only to drugs that are CYP2D6 prodrugs requiring activation (such as codeine); paroxetine is already pharmacologically active and its plasma concentrations are not affected by residual CYP2D6 inhibition because active drugs use different elimination pathways
E) The relevant concern is not CYP2D6 inhibition but induction: terbinafine induces CYP2D6 during treatment, and the induction effect persists for six to eight weeks post-discontinuation; paroxetine started at three weeks would therefore be rapidly metabolized and potentially subtherapeutic
ANSWER: C
Rationale:
Terbinafine produces mechanism-based (irreversible) inhibition of CYP2D6 by generating a reactive intermediate during CYP2D6-mediated metabolism that covalently inactivates the enzyme. Because the inactivation is irreversible, recovery of CYP2D6 activity is entirely dependent on de novo synthesis of new enzyme protein, not on elimination of terbinafine from the circulation. The half-life of CYP2D6 enzyme protein turnover is approximately one to two weeks, meaning that at three weeks post-terbinafine, a substantial proportion of the original CYP2D6 enzyme pool may still be inactivated and not yet replaced. Paroxetine is both a CYP2D6 substrate and itself a potent CYP2D6 inhibitor; when initiated in a patient with already reduced CYP2D6 activity from residual terbinafine effect, paroxetine clearance will be lower than expected, leading to accumulation at a given dose. The clinical implication is that paroxetine should be started at the lower end of the dose range with careful titration, and prescribers should be aware that CYP2D6 activity may not have fully recovered three weeks after terbinafine completion.
Option A: Option A is incorrect because terbinafine's plasma elimination half-life and its duration of CYP2D6 inhibition are governed by entirely different processes; terbinafine can be eliminated from plasma while CYP2D6 remains inactivated, because enzyme recovery requires new protein synthesis rather than drug clearance.
Option B: Option B is incorrect because while terbinafine does persist in keratinized tissues (nail, skin) after discontinuation, the systemic levels released from these depots are generally not sufficient to drive ongoing pharmacokinetic drug interactions at three weeks; the persisting CYP2D6 inhibition is due to the irreversible mechanism-based nature of the enzyme inactivation, not continued drug release from nail tissue.
Option D: Option D is incorrect because residual CYP2D6 inhibition applies to any CYP2D6 substrate — both prodrugs requiring activation (codeine) and active drugs requiring inactivation (paroxetine, metoprolol, many antidepressants and antipsychotics); the distinction between prodrug and active drug does not determine CYP2D6 relevance.
Option E: Option E is incorrect because terbinafine inhibits rather than induces CYP2D6; post-discontinuation CYP2D6 induction by terbinafine is not a pharmacological mechanism and the stated six-to-eight week induction persistence is fabricated.
6. An ophthalmology consultant requests infectious disease input for a patient with candidemia who has developed Candida endophthalmitis with vitreal involvement. The ID fellow notes that most systemic antifungals achieve poor vitreal drug concentrations. A senior resident asks why flucytosine is considered a useful adjunct agent in Candida endophthalmitis despite not being widely used for other Candida infections. Which pharmacokinetic property of flucytosine best explains its utility in this setting?
A) Flucytosine is highly lipophilic with a large volume of distribution, allowing it to concentrate in the lipid-rich vitreous humor at levels several times higher than concurrent plasma concentrations, similar to its behavior in other lipid-rich compartments such as adipose tissue
B) Flucytosine undergoes active transport into the vitreous humor by a specialized ocular transporter related to the retinal cytosine permease system; this concentrating mechanism produces vitreal levels that are three to four times plasma concentrations
C) Flucytosine achieves adequate vitreal penetration because it is administered by intravitreal injection in endophthalmitis; systemic oral or intravenous flucytosine does not penetrate the vitreous humor in clinically relevant concentrations
D) Flucytosine is hydrophilic, minimally protein-bound (approximately 4%), and has a volume of distribution approximating total body water; these properties allow it to distribute freely into aqueous body compartments including the vitreous humor, achieving vitreal drug concentrations sufficient for antifungal activity as an adjunct to primary therapy
E) Flucytosine's vitreal penetration is irrelevant to its role in endophthalmitis; it is used because it is the only antifungal with activity against Candida biofilms formed on the vitreous surface, a property unrelated to pharmacokinetics
ANSWER: D
Rationale:
Flucytosine's clinical utility in Candida endophthalmitis is grounded in its pharmacokinetic properties. It is a small, hydrophilic molecule with minimal plasma protein binding of approximately 4% and a volume of distribution of approximately 0.6 L/kg corresponding to total body water. These characteristics enable flucytosine to distribute freely into aqueous compartments throughout the body. The vitreous humor, while anatomically sequestered behind the blood-retinal barrier, is an aqueous compartment; drugs that are hydrophilic, small, and minimally protein-bound can penetrate the blood-retinal barrier more effectively than lipophilic, large, or highly protein-bound molecules. Flucytosine achieves meaningful vitreal drug concentrations after systemic administration, providing antifungal activity at the site of ocular infection as an adjunct to fluconazole (the primary agent for Candida endophthalmitis). The same pharmacokinetic properties that underpin flucytosine's excellent cerebrospinal fluid penetration (70–85% of plasma) also explain its vitreal distribution.
Option A: Option A is incorrect because flucytosine is hydrophilic, not lipophilic; it does not concentrate in lipid-rich compartments and does not have a large volume of distribution. The description of flucytosine as lipophilic is the opposite of its actual physicochemical character.
Option B: Option B is incorrect because no specialized active ocular transporter concentrating flucytosine in the vitreous to three to four times plasma levels has been established; flucytosine's ocular penetration reflects passive distribution driven by its hydrophilic, low-protein-binding properties, not active concentration by a retinal permease.
Option C: Option C is incorrect because systemic oral or intravenous flucytosine does achieve clinically relevant vitreal concentrations; intravitreal injection of flucytosine is not the standard route used for endophthalmitis management, and the value of flucytosine in this setting is its systemic distribution into the vitreous, not local injection.
Option E: Option E is incorrect because flucytosine does not have uniquely superior anti-biofilm activity against Candida compared to other antifungals; its utility in endophthalmitis is pharmacokinetic (vitreal penetration) rather than pharmacodynamic selectivity for biofilm-associated organisms.
7. A 32-year-old man taking griseofulvin for tinea capitis attends a social event and consumes three glasses of wine. Within 30 minutes he develops flushing, pounding headache, tachycardia, nausea, and diaphoresis. His wife, who is a nurse, recognizes this as a drug-alcohol interaction. Which of the following correctly identifies the biochemical mechanism and the intermediate metabolite responsible for this reaction?
A) Griseofulvin inhibits CYP2E1 (cytochrome P450 2E1), the hepatic enzyme primarily responsible for converting ethanol to acetaldehyde; reduced conversion slows ethanol clearance, and the resulting high blood ethanol concentration directly causes vasodilatation, tachycardia, and flushing through direct ethanol toxicity rather than through acetaldehyde accumulation
B) Griseofulvin inhibits aldehyde dehydrogenase (ALDH2), the enzyme responsible for oxidizing acetaldehyde to acetate in ethanol metabolism; acetaldehyde accumulates in plasma to toxic concentrations, directly causing vasodilatation, tachycardia, flushing, nausea, and diaphoresis — the same mechanism as the therapeutic disulfiram reaction used in alcohol use disorder treatment
C) Griseofulvin's CYP3A4 induction increases the rate of ethanol oxidation to acetaldehyde without a compensatory increase in acetaldehyde clearance, producing a transient acetaldehyde surplus; the surplus is self-limiting because compensatory ALDH2 upregulation resolves the reaction within two hours without treatment
D) Griseofulvin competes with ethanol for alcohol dehydrogenase (ADH1), the enzyme that converts ethanol to acetaldehyde; by reducing the conversion rate, griseofulvin decreases acetaldehyde production, paradoxically improving ethanol tolerance and producing a stimulant rather than aversive reaction to alcohol
E) Griseofulvin inhibits monoamine oxidase (MAO), which normally degrades vasoactive amines present in wine such as tyramine and histamine; tyramine accumulation from impaired MAO degradation produces a hypertensive reaction that mimics a disulfiram response but is pharmacodynamically distinct from acetaldehyde accumulation
ANSWER: B
Rationale:
Griseofulvin inhibits aldehyde dehydrogenase (ALDH2), the mitochondrial enzyme responsible for the second step in ethanol metabolism: oxidation of acetaldehyde to acetate. When ALDH2 is inhibited, acetaldehyde — the first and toxic intermediate of ethanol oxidation — accumulates in plasma and tissues. Acetaldehyde is a highly reactive aldehyde that directly causes vasodilatation, increased heart rate, cutaneous flushing, nausea, diaphoresis, and headache by multiple mechanisms including mast cell degranulation, direct vascular smooth muscle effects, and catecholamine release. This is the same mechanism by which disulfiram (Antabuse) produces its aversive reaction in patients treated for alcohol use disorder. The griseofulvin-alcohol interaction is unpredictable in severity and does not occur in all patients, but patients prescribed griseofulvin should be counseled to avoid alcohol during the entire treatment course.
Option A: Option A is incorrect because griseofulvin does not clinically inhibit CYP2E1; the relevant enzyme is ALDH2, which acts downstream of ethanol-to-acetaldehyde conversion, and the symptoms are not caused by direct ethanol toxicity from accumulation of the parent alcohol.
Option C: Option C is incorrect because griseofulvin does not accelerate acetaldehyde production through CYP3A4 induction of ethanol oxidation; the CYP3A4 induction activity of griseofulvin applies to steroid hormone and drug metabolism, not to ethanol oxidation, and the reaction is not self-limiting through compensatory ALDH2 upregulation.
Option D: Option D is incorrect because griseofulvin does not competitively inhibit alcohol dehydrogenase (ADH1); its relevant target in ethanol metabolism is ALDH2 downstream, not ADH1 upstream. Inhibiting ADH1 would reduce acetaldehyde production, not increase it.
Option E: Option E is incorrect because griseofulvin is not a monoamine oxidase inhibitor; MAO inhibitor-tyramine interactions produce hypertensive crises rather than flushing-dominant acetaldehyde-type reactions, and wine-associated tyramine accumulation through MAO inhibition is a distinct pharmacological mechanism unrelated to griseofulvin.
8. A patient completing a 12-week course of oral terbinafine for toenail onychomycosis asks why only 12 weeks of treatment is needed when the toenail will take 12 to 18 months to grow out fully and replace the infected nail. The physician explains that terbinafine has a tissue pharmacokinetic property that makes the brief treatment course effective. Which property best explains this phenomenon?
A) Terbinafine is lipophilic and concentrates in keratin-rich tissues including the nail plate, nail bed, and skin; it continues to be released slowly from nail keratin for months after the last oral dose, maintaining antifungal drug concentrations at the site of dermatophyte infection long after plasma concentrations have become undetectable
B) Terbinafine forms covalent bonds with keratin protein in the nail plate that are only broken by fungal keratinase enzymes; by binding to keratin, terbinafine acts as a molecular bait that lures dermatophytes to the drug-keratin complex, where the drug is released locally at the site of fungal keratinase activity
C) Terbinafine is converted in the nail bed to a stable sulfoxide metabolite that has a plasma half-life of six months; this metabolite is deposited in the proximal nail matrix and grows outward with the nail over the full 12 to 18-month nail replacement cycle, providing continuous drug delivery during outgrowth
D) Terbinafine stimulates nail matrix keratinocyte proliferation, accelerating the outgrowth of new drug-free nail that displaces infected nail distally; the 12-week course provides sufficient acceleration of nail growth to achieve complete replacement of infected nail within the treatment period itself
E) Terbinafine is incorporated into the nail plate as an inactive prodrug during the treatment course; dermatophyte-expressed squalene epoxidase in the nail converts it back to the active inhibitor form locally, so treatment needs only last long enough to deposit prodrug throughout the nail matrix
ANSWER: A
Rationale:
Terbinafine is a highly lipophilic molecule with strong affinity for keratin-rich tissues. After oral administration, it distributes rapidly and extensively into the stratum corneum, hair, and nails, achieving concentrations in these keratinized tissues that substantially exceed plasma concentrations. Critically, terbinafine is retained in nail keratin for months after oral therapy is discontinued — nail concentrations remain detectable and antifungally active for up to three months or longer after the last dose. This prolonged tissue retention means that although the 12-week treatment course ends well before nail outgrowth is complete, sufficient terbinafine remains sequestered in the growing nail to continue inhibiting any residual dermatophyte activity as the infected nail slowly grows out and is replaced by drug-impregnated new nail from the proximal matrix. This pharmacokinetic property is the reason that terbinafine's treatment course (12 weeks for toenails) is dramatically shorter than the nail replacement time (12–18 months) yet achieves high mycological cure rates.
Option B: Option B is incorrect because terbinafine does not form covalent bonds with keratin protein or function as a molecular bait; its retention in keratinized tissue reflects physicochemical partitioning due to lipophilicity, not covalent attachment or enzyme-triggered release.
Option C: Option C is incorrect because terbinafine does not form a stable six-month sulfoxide metabolite that is deposited in the nail matrix; its metabolites are formed hepatically and eliminated renally, and no such long-lived keratin-deposited metabolite has been established as the mechanism for prolonged nail activity.
Option D: Option D is incorrect because terbinafine does not accelerate nail matrix keratinocyte proliferation or nail growth rate; its pharmacological activity is entirely antifungal through squalene epoxidase inhibition, not through effects on nail keratinocyte kinetics.
Option E: Option E is incorrect because terbinafine is not incorporated into the nail as an inactive prodrug requiring fungal enzyme activation; it is active in its parent form and does not depend on dermatophyte squalene epoxidase for conversion to an active state — it inhibits that enzyme rather than being activated by it.
9. A patient with cryptococcal meningitis and rapidly worsening acute kidney injury (AKI) is receiving amphotericin B plus flucytosine. Serum creatinine has risen from 1.1 to 3.8 mg/dL over the past 48 hours. The resident proposes using a standard renal-dose adjustment table to reduce the flucytosine dose based on the current creatinine. The attending disagrees and requests a different approach. Which statement best explains the attending's reasoning?
A) Renal dose adjustment tables for flucytosine are calibrated for patients receiving concurrent amphotericin B, and the attending objects because the standard table overestimates the required dose reduction in the setting of amphotericin-induced nephrotoxicity compared to intrinsic renal disease
B) Standard renal dose adjustment tables for flucytosine should not be used in AKI because AKI patients have artificially elevated creatinine due to muscle breakdown from critical illness; the true GFR (glomerular filtration rate) is substantially better than the creatinine suggests, and dose reduction based on the elevated creatinine would result in subtherapeutic flucytosine levels
C) The attending objects because flucytosine dose adjustment tables were derived from patients with chronic kidney disease, not AKI; in AKI, the drug should not be dose-adjusted at all because the kidneys retain tubular secretion capacity even when glomerular filtration falls, maintaining adequate flucytosine excretion
D) The attending prefers empiric cessation of flucytosine until creatinine stabilizes, because no reliable dosing strategy exists for flucytosine in rapidly changing renal function and continuing the drug during active AKI always produces toxic concentrations regardless of the dose used
E) When renal function is changing rapidly, a creatinine value obtained today may not accurately reflect actual flucytosine clearance over the next dosing interval; TDM (therapeutic drug monitoring) with direct measurement of flucytosine plasma concentrations provides a real-time assessment of actual drug exposure that fixed creatinine-based tables cannot replicate in a dynamically evolving clinical situation
ANSWER: E
Rationale:
Standard renal dose adjustment tables for flucytosine are designed for patients with stable renal function; they estimate drug clearance from a measured creatinine or calculated CrCl (creatinine clearance) value and recommend a fixed dose or interval. This approach is reliable when renal function is stable because today's creatinine predicts tomorrow's clearance with reasonable accuracy. However, when renal function is changing rapidly — as in this patient whose creatinine has risen from 1.1 to 3.8 mg/dL over 48 hours — the creatinine measured at any point in time may substantially underestimate or overestimate the actual clearance available during the next dosing interval. A creatinine-based table dose is therefore a lagging estimate, not a real-time measure. TDM with direct measurement of 2-hour post-dose flucytosine peak concentrations provides actual drug exposure data that reflects the patient's current clearance regardless of how rapidly it is changing. Targeting peaks at 25 to 50 mg/L while monitoring troughs to stay below 100 mg/L allows safe continuation of flucytosine through the AKI episode with the optimal balance of efficacy and myelosuppression risk. This is explicitly recommended in published guidelines for patients with fluctuating renal function receiving flucytosine.
Option A: Option A is incorrect because standard renal dose adjustment tables are not specifically calibrated or differentiated by AKI etiology; the attending's objection is that creatinine-based tables are unreliable in any rapidly changing renal function scenario, not that different tables apply to amphotericin nephrotoxicity versus intrinsic renal disease.
Option B: Option B is incorrect because the argument that creatinine is falsely elevated due to muscle breakdown would support using a lower dose reduction than the table suggests — not abandoning the table approach for TDM. Furthermore, the patient has documented progressively rising creatinine from a nephrotoxic agent, not a critically ill patient with rhabdomyolysis-inflated creatinine.
Option C: Option C is incorrect because tubular secretion is not a significant clearance pathway for flucytosine; the drug is eliminated predominantly by glomerular filtration of unchanged drug, and a claim that tubular secretion maintains adequate excretion during AKI is pharmacokinetically inaccurate.
Option D: Option D is incorrect because stopping flucytosine removes its proven benefit in the combination induction regimen; TDM-guided continuation is the appropriate management, and the premise that all AKI patients will develop toxic concentrations regardless of dose is not supported by clinical evidence.
10. A renal transplant patient on stable cyclosporine immunosuppression develops tinea capitis caused by Microsporum canis. Cyclosporine is a CYP3A4 (cytochrome P450 3A4) substrate with a narrow therapeutic index, and its trough levels are currently well within the therapeutic range. The transplant team is asked whether griseofulvin is safe to use. Which of the following best describes the pharmacokinetic interaction and its clinical consequence?
A) Griseofulvin inhibits CYP3A4, reducing cyclosporine metabolism and causing toxic cyclosporine accumulation; this would produce nephrotoxicity, neurotoxicity, and hypertension, making griseofulvin absolutely contraindicated in all transplant patients regardless of the causative tinea species
B) Griseofulvin and cyclosporine compete for the same P-glycoprotein (P-gp) efflux transporter in the small intestinal mucosa; griseofulvin saturates P-gp, reducing cyclosporine efflux and increasing its oral bioavailability, resulting in elevated trough levels requiring dose reduction
C) Griseofulvin induces CYP3A4, increasing the rate of cyclosporine metabolism in the liver and intestinal wall; cyclosporine trough levels will fall, potentially dropping below the therapeutic range and increasing the risk of acute rejection; if griseofulvin must be used, frequent cyclosporine monitoring and likely dose escalation are required
D) Griseofulvin has no clinically relevant interaction with cyclosporine because cyclosporine's narrow therapeutic index is protected by its extensive protein binding (approximately 90%), which buffers against changes in free drug concentration caused by metabolic induction
E) Griseofulvin reduces cyclosporine bioavailability through a pharmacodynamic rather than pharmacokinetic mechanism; it activates calcineurin in T lymphocytes by a mechanism independent of CYP3A4, counteracting cyclosporine's calcineurin inhibition and reducing the net immunosuppressive effect without changing plasma cyclosporine concentrations
ANSWER: C
Rationale:
Griseofulvin is an inducer of CYP3A4 and CYP1A2. Cyclosporine is a substrate of both CYP3A4 and P-glycoprotein, and its oral bioavailability and systemic clearance are heavily dependent on CYP3A4 activity in both the intestinal wall and the liver. When griseofulvin induces CYP3A4, the rate of cyclosporine metabolism increases, reducing peak concentrations after each dose and lowering trough levels. Because cyclosporine has a narrow therapeutic index — with subtherapeutic troughs predisposing to acute rejection and supratherapeutic troughs producing nephrotoxicity and other toxicities — this CYP3A4 induction interaction is clinically significant and potentially dangerous in a transplant patient. If griseofulvin must be used, frequent measurement of cyclosporine trough levels and likely dose increases are required during the course of griseofulvin, with corresponding dose reduction when griseofulvin is stopped as induced CYP3A4 activity returns to baseline. Alternative antifungals with less CYP3A4 induction potential (such as terbinafine for Trichophyton species) should be considered, though terbinafine is less effective for Microsporum canis.
Option A: Option A is incorrect because griseofulvin induces CYP3A4 (increasing cyclosporine metabolism and lowering levels) rather than inhibiting it; CYP3A4 inhibitors such as azole antifungals cause the opposite interaction — cyclosporine accumulation — and the clinical risk with griseofulvin is rejection from subtherapeutic cyclosporine rather than toxicity from accumulation.
Option B: Option B is incorrect because griseofulvin is not a clinically significant P-glycoprotein inhibitor; the relevant interaction is CYP3A4 induction reducing hepatic and intestinal cyclosporine metabolism, not P-gp saturation increasing cyclosporine oral bioavailability.
Option D: Option D is incorrect because protein binding does not protect against metabolic drug interactions; it is the unbound fraction of cyclosporine that is metabolized by CYP3A4, and increased metabolic rate reduces total drug exposure regardless of protein binding status.
Option E: Option E is incorrect because griseofulvin does not activate calcineurin or counteract cyclosporine's pharmacodynamic effect through any direct immunological mechanism; the interaction is entirely pharmacokinetic, mediated through CYP3A4 induction reducing cyclosporine plasma concentrations.
11. A dermatologist asks whether an azole-resistant Trichophyton rubrum isolate causing onychomycosis would also be resistant to terbinafine. A clinical pharmacologist explains that the two drug classes do not share cross-resistance. Which mechanistic principle best explains why azole resistance in a dermatophyte does not confer terbinafine resistance?
A) Azole resistance in dermatophytes develops through efflux pump overexpression that is specific to azole molecular structure; terbinafine has a different molecular shape and is not recognized by CDR1/MDR1 efflux pumps, rendering pump-mediated azole resistance ineffective against terbinafine regardless of pump expression level
B) Terbinafine and azoles both target the ergosterol biosynthesis pathway but at different enzymatic steps; however, resistance to either class occurs through membrane composition changes that equally reduce intracellular drug accumulation for both classes, so cross-resistance is theoretically possible but uncommon in clinical isolates
C) Terbinafine resistance in dermatophytes has never been reported; cross-resistance is therefore not a concern because terbinafine cannot be overcome by any resistance mechanism currently identified in fungi
D) Terbinafine inhibits squalene epoxidase, while azoles inhibit CYP51 (lanosterol 14-alpha-demethylase); these are distinct enzymes at different steps in the ergosterol biosynthesis pathway, so mutations or overexpression affecting one target do not alter the function or expression of the other, and resistance mutations at CYP51 do not confer resistance at squalene epoxidase
E) Terbinafine and azoles target the same enzyme (squalene epoxidase) but bind at different sites on the enzyme; mutations at the azole binding site change the active site geometry in a way that actually increases terbinafine binding affinity, explaining why azole-resistant isolates are often more susceptible to terbinafine
ANSWER: D
Rationale:
Terbinafine and the azole antifungals both act on the ergosterol biosynthesis pathway, but they target distinct enzymes at different steps. Terbinafine inhibits squalene epoxidase (also called squalene monooxygenase), which converts squalene to 2,3-oxidosqualene — an early step in the pathway. Azoles (fluconazole, itraconazole, voriconazole, etc.) inhibit CYP51 (lanosterol 14-alpha-demethylase), which converts lanosterol to 4,4-dimethylcholesta-8,14,24-trienol — a downstream step. Because these are entirely separate enzyme proteins encoded by different genes, resistance mechanisms targeting one do not affect the other. The most common mechanism of azole resistance in dermatophytes involves mutations in the CYP51 gene (producing a target with reduced azole binding) or upregulation of CYP51 expression; neither of these mechanisms has any structural or functional consequence for squalene epoxidase. Similarly, the most common mechanism of terbinafine resistance involves mutations in the squalene epoxidase gene (SQLE) that reduce terbinafine binding; these mutations do not affect CYP51. This target-specificity of resistance is the basis for the lack of cross-resistance between the two classes, and it means that an azole-resistant dermatophyte may remain fully susceptible to terbinafine and vice versa.
Option A: Option A is incorrect because while efflux pump-mediated resistance is one potential mechanism for azole resistance, the key explanation for absence of cross-resistance is the distinct enzymatic targets, not specificity of efflux pump substrate recognition; the mechanistic explanation at the enzyme level is more fundamental.
Option B: Option B is incorrect because resistance to either class does not typically arise from membrane composition changes that equally reduce accumulation of both; the dominant mechanisms are target-specific mutations, and the statement that cross-resistance is possible but uncommon understates the mechanistic independence of the two targets.
Option C: Option C is incorrect because terbinafine resistance in dermatophytes has been reported, most commonly through point mutations in the squalene epoxidase gene (SQLE); dismissing the possibility of resistance misrepresents the microbiology literature.
Option E: Option E is incorrect because terbinafine and azoles target different enzymes — squalene epoxidase and CYP51 respectively — not different sites on the same enzyme; the premise that they share a target is incorrect.
12. A clinical microbiologist is reviewing antifungal susceptibility testing policies. She notes that flucytosine susceptibility testing is ordered reflexively for some Candida species but not others. Which statement correctly describes why Candida glabrata (now reclassified as Nakaseomyces glabrata) requires susceptibility testing before flucytosine is considered for use?
A) C. glabrata is universally and predictably resistant to flucytosine at all institutions worldwide; susceptibility testing is ordered as a confirmatory step only for medicolegal documentation purposes before withholding the drug
B) C. glabrata has variable and institution-dependent flucytosine resistance rates; some isolates carry pre-existing mutations in the activation pathway (cytosine permease, cytosine deaminase, or URA enzymes) while others remain susceptible, making susceptibility testing essential to guide whether flucytosine can be included in a combination regimen
C) C. glabrata is inherently susceptible to flucytosine but acquires resistance so rapidly during combination therapy that testing the initial isolate is futile; surveillance cultures after 48 hours of treatment are more informative than baseline susceptibility testing
D) C. glabrata has uniform intermediate susceptibility to flucytosine at all institutions; the MIC (minimum inhibitory concentration) is reliably in the intermediate range (16 to 32 mg/L), and dose escalation to achieve adequate drug concentrations above the intermediate MIC is standard practice without formal susceptibility breakpoint testing
E) Flucytosine susceptibility testing is unnecessary for C. glabrata because the drug should never be used as monotherapy; since it is always administered in combination, any individual isolate's flucytosine susceptibility is pharmacodynamically irrelevant to the combination regimen's outcome
ANSWER: B
Rationale:
Unlike Candida krusei (Pichia kudriavzevii), which is uniformly and intrinsically resistant to flucytosine, C. glabrata (Nakaseomyces glabrata) has variable resistance rates. Some C. glabrata isolates carry pre-existing loss-of-function mutations in the flucytosine activation pathway — cytosine permease, cytosine deaminase, or URA3/URA5 phosphorylation enzymes — and are resistant before any drug exposure. Other isolates from different patients, institutions, or geographic regions remain susceptible. Resistance rates in C. glabrata vary between published studies and between healthcare institutions, reflecting differences in prior antifungal exposure in patient populations, institutional prescribing practices, and geographic variation in fungal population genetics. This variability means that clinicians cannot assume susceptibility or resistance without testing, and susceptibility testing results should guide whether flucytosine is included in combination therapy for serious C. glabrata infections.
Option A: Option A is incorrect because C. glabrata is not universally resistant to flucytosine; universal intrinsic resistance is the characteristic of C. krusei, not C. glabrata, where resistance is variable and needs to be determined for each isolate.
Option C: Option C is incorrect because even though secondary resistance can develop during monotherapy, baseline susceptibility testing of the initial isolate is clinically relevant to determine whether flucytosine provides any antifungal activity from the start of treatment; a resistant isolate at baseline would not benefit from flucytosine inclusion at any point in therapy.
Option D: Option D is incorrect because C. glabrata does not have uniformly intermediate flucytosine MICs; its resistance pattern is variable rather than predictably intermediate, and a uniform dose-escalation approach based on assumed intermediate MICs misrepresents the microbiology.
Option E: Option E is incorrect because individual organism susceptibility remains relevant even in combination therapy; a combination regimen that includes flucytosine against a resistant organism contributes only the other drug's activity to the combination while exposing the patient to flucytosine's toxicity risk without antifungal benefit.
13. A 42-year-old man is currently in week 8 of a 12-week oral terbinafine course for confirmed Trichophyton rubrum onychomycosis of the toenails. His 7-year-old daughter is diagnosed with tinea capitis, and scalp culture returns positive for Microsporum canis. She is treated with griseofulvin. The father subsequently develops a new scaling scalp lesion; culture confirms Microsporum canis tinea capitis, presumably acquired from his daughter. The physician must decide whether the current terbinafine course adequately covers both infections. Which statement correctly integrates the relevant pharmacological concepts to guide this decision?
A) Although terbinafine achieves excellent concentrations in keratinized tissues including hair follicles, comparative trial data demonstrate lower mycological cure rates for terbinafine against Microsporum canis compared to Trichophyton species; continuing terbinafine alone is unlikely to adequately treat the M. canis tinea capitis, and griseofulvin should be added or substituted as the primary agent for the scalp infection
B) Terbinafine is appropriate for both infections because it achieves fungicidal concentrations in both nail and hair follicle keratin; the same pharmacokinetic property — lipophilic accumulation in keratinized tissue — that enables effective treatment of T. rubrum onychomycosis provides equivalent coverage of M. canis tinea capitis at the standard 250 mg daily dose
C) Terbinafine should be discontinued and griseofulvin substituted for both infections simultaneously; this is necessary because griseofulvin, as a microtubule inhibitor, has broader anti-dermatophyte activity than terbinafine and will cover both M. canis and T. rubrum more reliably than continued terbinafine
D) The M. canis tinea capitis will self-resolve once the daughter's infection is treated and the source of re-exposure is eliminated; the terbinafine course should continue without modification because pharmacokinetic drug levels in the scalp skin are sufficient to prevent establishment of a new M. canis scalp infection even if the organism is not fully eradicated
E) The physician should increase the terbinafine dose to 500 mg daily for the remaining four weeks; higher doses overcome the reduced susceptibility of Microsporum canis to terbinafine's squalene epoxidase inhibition and have been demonstrated to achieve equivalent mycological cure rates to griseofulvin for M. canis tinea capitis in pediatric dose-escalation trials
ANSWER: A
Rationale:
This question requires integrating two distinct pharmacological concepts: terbinafine's tissue pharmacokinetics and its species-specific efficacy profile for tinea capitis. Terbinafine does achieve excellent concentrations in hair follicle and scalp keratin after oral dosing — the same lipophilic, keratin-avid tissue distribution that benefits nail infections applies equally to scalp and hair. However, tissue penetration alone does not guarantee clinical efficacy if the organism is insufficiently susceptible to the drug. Comparative trials for tinea capitis have consistently demonstrated that terbinafine achieves lower mycological cure rates against Microsporum canis than against Trichophyton tonsurans and Trichophyton violaceum. For Trichophyton-caused tinea capitis, terbinafine is preferred and produces high cure rates; for Microsporum canis-caused tinea capitis, griseofulvin is preferred because terbinafine's cure rates for this species are substantially lower. In this patient, continuing terbinafine alone would be appropriate for the toenail T. rubrum infection — where terbinafine is the optimal agent — but would be unlikely to reliably eradicate the new M. canis scalp infection, where griseofulvin has demonstrated superior efficacy. Adding griseofulvin for the scalp infection or substituting it as the primary treatment for the M. canis disease is the correct approach.
Option B: Option B is incorrect because it conflates pharmacokinetic tissue distribution (excellent for terbinafine in all keratinized tissues) with pharmacodynamic efficacy against specific organisms; adequate tissue concentrations of a drug are necessary but not sufficient for clinical cure if the organism's susceptibility to that drug is reduced — which is exactly the case for M. canis and terbinafine.
Option C: Option C is incorrect because griseofulvin does not have broader anti-dermatophyte activity than terbinafine; both agents have similar species coverage within the dermatophyte class in terms of in vitro susceptibility, but the clinical efficacy difference for M. canis versus Trichophyton is specific to terbinafine, not a reflection of broader griseofulvin spectrum. Substituting griseofulvin for the T. rubrum onychomycosis would be inappropriate given terbinafine's established superiority for that indication.
Option D: Option D is incorrect because M. canis tinea capitis does not self-resolve in an adult with an active scalp infection; active treatment is required, and the source-control argument (treating the daughter) does not substitute for treating the father's established active infection.
Option E: Option E is incorrect because dose escalation of terbinafine to 500 mg daily for M. canis tinea capitis has not been established in controlled trials as achieving equivalent cure rates to griseofulvin, and this approach would expose the patient to increased adverse effect risk without proven efficacy benefit.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.